{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:37:48Z","timestamp":1794559068531,"version":"4.9.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.biopha.2022.114170","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T13:02:04Z","timestamp":1672405324000},"page":"114170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice"],"prefix":"10.1016","volume":"158","author":[{"given":"Amir Abbas","family":"Momtazi-Borojeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Abbas","family":"Tabatabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.biopha.2022.114170_bib1","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.biopha.2022.114170_bib2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.biopha.2022.114170_bib3","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"22","key":"10.1016\/j.biopha.2022.114170_bib4","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the glagov randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.biopha.2022.114170_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","article-title":"Inhibiting PCSK9 \u2014 biology beyond LDL control","volume":"15","author":"Stoekenbroek","year":"2018","journal-title":"Nat. Rev. Endocrionol."},{"issue":"13","key":"10.1016\/j.biopha.2022.114170_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11133625","article-title":"Non-lipid effects of PCSK9 monoclonal antibodies on vessel wall","volume":"11","author":"Ugovsek","year":"2022","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.biopha.2022.114170_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111758","article-title":"PCSK9 and cancer: rethinking the link","volume":"140","author":"Mahboobnia","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.biopha.2022.114170_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8101742","article-title":"Association of serum PCSK9 levels with antibiotic resistance and severity of disease in patients with bacterial infections admitted to intensive care units","volume":"8","author":"Jamialahmadi","year":"2019","journal-title":"J. Clin. Med"},{"issue":"4","key":"10.1016\/j.biopha.2022.114170_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur. Heart J. -Cardiovasc. Pharmacother."},{"key":"10.1016\/j.biopha.2022.114170_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.phrs.2017.03.023","article-title":"Regulation of PCSK9 by nutraceuticals","volume":"120","author":"Momtazi","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.biopha.2022.114170_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.drudis.2017.01.006","article-title":"PCSK9 and diabetes: is there a link?","volume":"22","author":"Momtazi","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.biopha.2022.114170_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13543784.2017.1272570","article-title":"PCSK9 inhibitors in sepsis: a new potential indication?","volume":"26","author":"Momtazi","year":"2017","journal-title":"Expert Opin Investig Drugs."},{"key":"10.1016\/j.biopha.2022.114170_bib13","first-page":"234","article-title":"Overview of the current status of familial hypercholesterolaemia care in over 60 countries - the EAS familial hypercholesterolaemia studies collaboration (FHSC)","author":"Vallejo-Vaz","year":"2018"},{"issue":"1","key":"10.1016\/j.biopha.2022.114170_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.biopha.2022.114170_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-012-0345-z","article-title":"PCSK9 Inhibitors: potential in cardiovascular therapeutics","volume":"15","author":"Do","year":"2013","journal-title":"Curr. Cardiol. Rep."},{"issue":"7444","key":"10.1016\/j.biopha.2022.114170_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/496152a","article-title":"A gene of rare effect","volume":"496","author":"Hall","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2022.114170_bib17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","article-title":"New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?","volume":"27","author":"Sahebkar","year":"2013","journal-title":"Cardiovasc Drugs Ther."},{"issue":"1","key":"10.1016\/j.biopha.2022.114170_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","article-title":"Recent advances in pharmacotherapy for hypertriglyceridemia","volume":"56","author":"Sahebkar","year":"2014","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.biopha.2022.114170_bib19","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.M028340","article-title":"Immunization against proprotein convertase Subtilisin-like\/Kexin type 9 (PCSK9) lowers plasma LDL-cholesterol levels in mice","author":"Fattori","year":"2012","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.114170_bib20","doi-asserted-by":"crossref","first-page":"12534","DOI":"10.1038\/s41598-017-13069-w","article-title":"A therapeutic peptide vaccine against PCSK9","volume":"7","author":"Pan","year":"2017","journal-title":"Sci. Rep."},{"issue":"43","key":"10.1016\/j.biopha.2022.114170_bib21","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.biopha.2022.114170_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014358","article-title":"Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid \u03b2\u2010oxidation","volume":"9","author":"Wu","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"10.1016\/j.biopha.2022.114170_bib23","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1021\/acsbiomaterials.9b00434","article-title":"PCSK9 hapten multicopy displayed onto carrier protein nanoparticle: an antiatherosclerosis vaccine","volume":"5","author":"You","year":"2019","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"12","key":"10.1016\/j.biopha.2022.114170_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines-an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PloS One"},{"issue":"32","key":"10.1016\/j.biopha.2022.114170_bib25","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE* 3Leiden. CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.biopha.2022.114170_bib26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2174\/0929867328666211027125245","article-title":"PCSK9 inhibition-based therapeutic approaches: an immunotherapy perspective","volume":"29","author":"Momtazi-Borojeni","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2022.114170_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.atherosclerosis.2019.02.001","article-title":"Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system","volume":"283","author":"Momtazi-Borojeni","year":"2019","journal-title":"Atherosclerosis"},{"issue":"Supplement_1","key":"10.1016\/j.biopha.2022.114170_bib28","first-page":"ehz746","article-title":"P6195 Nanoliposomal anti-PCSK9 vaccine induces long-term and safe protection against atherosclerosis in C57BL\/6 mouse","volume":"40","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.biopha.2022.114170_bib29","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.5114\/aoms\/133885","article-title":"PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis","volume":"17","author":"Momtazi-Borojeni","year":"2021","journal-title":"Arch. Med. Sci.: AMS"},{"issue":"1","key":"10.1016\/j.biopha.2022.114170_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-019-1457-8","article-title":"Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis","volume":"17","author":"Momtazi-Borojeni","year":"2019","journal-title":"BMC Med."},{"issue":"Supplement_1","key":"10.1016\/j.biopha.2022.114170_bib31","doi-asserted-by":"crossref","first-page":"ehz746","DOI":"10.1093\/eurheartj\/ehz746.0799","article-title":"P6194 Therapeutic effect of nanoliposomal anti-PCSK9 vaccine on hypercholesterolemia and atherosclerosis in C57BL\/6 mice","volume":"40","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2022.114170_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5114\/aoms.2020.91291","article-title":"Effects of immunisation against PCSK9 in mice bearing melanoma","volume":"16","author":"Momtazi-Borojeni","year":"2020","journal-title":"Arch. Med. Sci.: AMS"},{"issue":"Supplement_1","key":"10.1016\/j.biopha.2022.114170_bib33","doi-asserted-by":"crossref","first-page":"ehz745","DOI":"10.1093\/eurheartj\/ehz745.0123","article-title":"4120 Anti-tumor activity of a nanoliposomal anti-PCSK9 vaccine in BALB\/c mice bearing 4T1 breast cancer","volume":"40","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur. Heart J."},{"issue":"Supplement_1","key":"10.1016\/j.biopha.2022.114170_bib34","first-page":"ehz747","article-title":"P673 Moderate anti-tumor effect of the nanoliposomal anti-PCSK9 vaccine in BALB\/c mice bearing colorectal cancer","volume":"40","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.biopha.2022.114170_bib35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5114\/aoms.2019.84732","article-title":"Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer","volume":"15","author":"Momtazi-Borojeni","year":"2019","journal-title":"Arch. Med. Sci.: AMS"},{"issue":"3","key":"10.1016\/j.biopha.2022.114170_bib36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.5114\/aoms.2019.84734","article-title":"Effects of immunization against PCSK9 in an experimental model of breast cancer","volume":"15","author":"Momtazi-Borojeni","year":"2019","journal-title":"Arch. Med. Sci.: AMS"},{"issue":"Supplement_1","key":"10.1016\/j.biopha.2022.114170_bib37","doi-asserted-by":"crossref","first-page":"ehz747","DOI":"10.1093\/eurheartj\/ehz747.0309","article-title":"P704 Nanoliposomal anti-PCSK9 vaccine ameliorates glucose intolerance and insulin resistance in diabetic rats","volume":"40","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2022.114170_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/4757170","article-title":"Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats","volume":"2021","author":"Momtazi-Borojeni","year":"2021","journal-title":"J. Diabetes Res."},{"issue":"6","key":"10.1016\/j.biopha.2022.114170_bib39","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch. Med. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2022.114170_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","article-title":"Development of AFFITOPE vaccines for Alzheimer\u2019s disease (AD)\u2014from concept to clinical testing","volume":"13","author":"Schneeberger","year":"2009","journal-title":"JNHA- J. Nutr., Health Aging"},{"issue":"6","key":"10.1016\/j.biopha.2022.114170_bib41","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/0003319709333868","article-title":"Determination of prooxidant--antioxidant balance after acute coronary syndrome using a rapid assay: a pilot study","volume":"60","author":"Ghayour-Mobarhan","year":"2009","journal-title":"Angiology"},{"key":"10.1016\/j.biopha.2022.114170_bib42","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/eurheartj\/ehab299","article-title":"PCSK9 vaccine: so near, yet so far!","volume":"42","author":"Sahebkar","year":"2021","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.biopha.2022.114170_bib43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1210\/en.2015-1376","article-title":"Daily fasting blood glucose rhythm in male mice: a role of the circadian clock in the liver","volume":"157","author":"Ando","year":"2016","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.biopha.2022.114170_bib44","first-page":"133","article-title":"Estimation of the normal range of blood glucose in rats","volume":"39","author":"Wang","year":"2010","journal-title":"Wei sheng yan jiu = J. Hyg. Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.114170_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.36349\/easjms.2022.v04i01.002","article-title":"Chronicity of Hepatotoxicity: A Review","volume":"4","author":"Bansal","year":"2022","journal-title":"EAS J. Med. Surg."},{"key":"10.1016\/j.biopha.2022.114170_bib46","series-title":"A Comprehensive Guide to Toxicology in Nonclinical Drug Development","first-page":"709","article-title":"Preclinical toxicology of vaccines, a comprehensive guide to toxicology in nonclinical drug development","author":"Green","year":"2017"},{"key":"10.1016\/j.biopha.2022.114170_bib47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.toxrep.2018.11.006","article-title":"Alterations of blood chemistry, hepatic and renal function, and blood cytometry in acrylamide-treated rats","volume":"5","author":"Rivadeneyra-Dom\u00ednguez","year":"2018","journal-title":"Toxicol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2022.114170_bib48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamacardio.2020.5341","article-title":"Genetic Inhibition of PCSK9 and liver function","volume":"6","author":"Rimbert","year":"2021","journal-title":"JAMA Cardiol."},{"issue":"7","key":"10.1016\/j.biopha.2022.114170_bib49","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","article-title":"Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Guedeney","year":"2022","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.biopha.2022.114170_bib50","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2022.114170_bib51","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"10.1016\/j.biopha.2022.114170_bib52","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2022.114170_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-017-0858-2","article-title":"Lipid management in chronic kidney disease: systematic review of PCSK9 targeting","volume":"78","author":"Zheng-Lin","year":"2018","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.biopha.2022.114170_bib54","first-page":"809","article-title":"PCSK9 and cardiovascular disease in individuals with moderately decreased kidney function","volume":"17","author":"Kheirkhah","year":"2022","journal-title":"Clin. J. Am. Soc."},{"issue":"4","key":"10.1016\/j.biopha.2022.114170_bib55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ame2.12139","article-title":"Clinical hematological and biochemical parameters in Swiss, BALB\/c, C57BL\/6 and B6D2F1 Mus musculus","volume":"3","author":"Silva\u2010Santana","year":"2020","journal-title":"Anim. Models Exp. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222015591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222015591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:38:40Z","timestamp":1779795520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222015591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":55,"alternative-id":["S0753332222015591"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114170","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114170"}}